On June 4th, Novo Nordisk China told reporters that according to approved US prescription information or EU product feature summaries, sexual dysfunction is not a side effect mentioned in the Wegovy (weight loss version of Smegglutide) instruction manual regarding the possible association between Smegglutide and male erectile dysfunction. Novo Nordisk was not involved in the execution or analysis of the study. The analysis results did not provide sufficient information on the dosage form and dosage (at the start and end of treatment) or treatment duration of Smegglutide. Therefore, it cannot be confirmed whether the dose of smeglutide evaluated in this study has been studied or approved for long-term weight management.
Novo Nordisk also mentioned that Novo Nordisk, Wegovy, and Novo Nordisk have been fully validated in clinical research and development projects, as well as large-scale real-world data studies, with a cumulative usage experience of over 11 million patients exposed to years.
Novo Nordisk stated that ensuring patient safety has always been its top priority. Novo Nordisk will continue to monitor adverse drug reactions, including sexual dysfunction, through routine drug vigilance. Novo Nordisk works closely with relevant institutions to ensure patient safety and provide sufficient information for healthcare professionals. (Pengpai News)